Top Life Sciences Startups in 2027

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Biodock is a cutting-edge, seed-stage bio AI startup backed by Andreessen Horowitz and Y Combinator seed blog post (blog.biodock.ai/announcing-seed-round). We are building the future of AI cloud computing for microscopy images, NGS sequencing data, and more. Advances in our technology translate directly to advances in disease understanding and treatment. We give our product for free to academic scientists as part of our mission to accelerate research around the world. Biodock's cloud platform accelerates microscopy analysis, automating months of microscopy analysis and infrastructure to minutes with our end-to-end AI architecture. Scientists enjoy auto-scaling storage, GPU compute, and 30-50% more accurate analysis. We're building an amazing experience to translate microscopy images to therapeutic insights for academic and enterprise scientists. We're a team of engineers/scientists from Stanford, Pinterest, and Facebook (4 strong, plus two contractors), in a beautiful office in Austin, TX. Join us!

At CancerIQ, our mission is to empower providers to offer genetic services at scale. Our solutions answer a growing problem of patient access by modeling proven systems at top academic cancer centers into a suite of digital health tools. - The CancerIQ Screening Toolkit and Navigator makes it easier for providers to efficiently identify high-risk patients, communicate that risk to patients, provide risk-based screening recommendations, and navigate them to genetic services. - The CancerIQ Self-Assessment and Specialist automates many of the tasks that are most time consuming for genetic specialists from gathering family history and running risk models, to processing test orders and generating documentation notes. - With the CancerIQ High-Risk Program and Manager providers can engage with high-risk patients over time with custom reminders to prompt follow-up activities and monitor care plans to ensure all recommendations are up to date.

Tombot makes robotic animals that transform the daily life of individuals, families and communities facing health adversities. Originally designed to meet the specific medical needs of seniors with dementia, Tombot Puppies have also been preordered for children with Autism, adults with high impact chronic pain, major depressive disorder, anxiety, bipolar disorder, and PTSD, and for long inpatient stays and arduous outpatient treatments at hospitals. Peer-reviewed studies show that robotic animals positively affect some users’ ability to cope with stress, anxiety, loneliness, depression and pain, reducing their need for psychotropic and opioid medications. Key Milestones and Metrics: • Completion of our 5th generation prototype and 3rd round of customers studies with 100s of seniors with dementia • Over 3,900 preorder and waitlist customers • Member of StartX: Stanford-funded startup accelerator program • Member of the Canadian Creative Destruction Lab accelerator program • Member of Children’s Hospital of Los Angeles accelerator program (CTIP) • Large-scale clinical trials in development with Children’s Hospital and the University of Southern California to demonstrate reduced stress, anxiety and pain for pediatric hospital inpatients • Large scale study in development with the LAC-USC Hospital Burn Unit to demonstrate reduced stress, anxiety, and pain for pediatric burn patients • Major national and international media coverage • Winner 2019 RoboBusiness Pitchfire competition • Filed multiple trademark, design and provisional utility patent applications • U.S. TAM: $9.0B (seniors with dementia plus mild cognitive impairment)

We kill cancers and viruses non-invasively using targeted heat, without side effects. Our proprietary nanoparticles seek out and attach to diseased cells or pathogens. Our HET system sends energy only to our nanoparticles, heating them up, curing the patient.

Vaxess's proprietary technology uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration, unlike existing products. Vaxess strives to lower the cost of distribution and increase access to vaccines for people around the world. - 2013 MassTLC Life Science Technology of the Year - 2013 HBS Alumni New Venture Program Winner - 2012 Harvard Business Plan Competition Winner - 2012 Harvard President's Challenge Winner - 2012 MassChallenge Finalist

At intellia, we are building a full-spectrum, product-driven biotechnology company focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. our approach to advancing the broad potential of genome editing includes our plans to enhance our crispr system. on the in vivo side, our systemic lipid nanoparticle or lnp-based delivery system, has the potential to unlock treatment of genetic diseases to both selectively knock out disease-causing genes and introduce targeted insertion of a functional gene. we are also focused on engineering t cell therapies to preserve normal cell physiology. ​our approach is designed to improve safety and efficacy by engineering cell therapies​ that are more precise, potent and persistent.

Impiricus Pulse. For doctors, it provides an opportunity to access curated clinical resources. For pharma, it is the most impactful channel to engage with their targets. Face-to-face access has diminished and Impiricus offers the only way to get in-depth connectivity. Impiricus Concierge. For doctors, its adds transparency and removes friction in accessing pharma resources. (Samples, Patient Support). For pharma is increases sales and ROI.

Our products will eventually be small molecule therapeutics that can treat various human diseases. Although our current focus is in the research and development of such therapeutics.

We built a pacemaker-like system that allows tinnitus and stroke patients to receive a novel therapy. The implanted device is connected to the vagus nerve in the neck and sends tiny pulses of electricity, which cause the brain to release chemicals called neurostransmitters. When these tiny pulses are paired with external stimulus such as tones or motor movements, specific regions of the brain are able to be rapidly rewired. Research was published in Nature and New England Journal of Medicine.